| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Licarbazepine targets voltage-gated sodium channels. By blocking sodium channels, it inhibits sodium influx, leading to a reduction in neuronal excitability. This mechanism is responsible for its anticonvulsant and mood-stabilizing effects. It potentiates minor GABAA receptor currents, which may also contribute to its anticonvulsant activity. It is the active metabolite of oxcarbazepine.
|
|---|---|
| ln Vitro |
In vitro, licarbazepine acts as a voltage-gated sodium channel blocker. It inhibits sodium influx in neuronal cells, reducing neuronal excitability. It potentiates minor GABAA receptor currents. Its activity is confirmed in electrophysiological assays using neuronal cell lines or primary neurons. Its purity is >99%.
|
| ln Vivo |
Eslicarbazepine acetate (ESL) is an oral prodrug that undergoes hydrolytic first-pass metabolism in the liver, which converts it into the physiologically active drug S-licarbazepine quickly and extensively. Prodrug plasma levels continue to be below quantitative thresholds [1]. The main areas of action for the powerful antiepileptic medication ESL are partial seizures and generalized tonic-clonic seizures. Its primary mode of action involves blocking sodium channels that are voltage-gated. Voltage-gated sodium channels, which are crucial for the production and spread of epileptic discharges, are blocked by ESL. When taken orally, ESL is highly absorbed and has a bioavailability that is roughly 16% greater than that of oxcarbazepine (OXC) at an equivalent dosage [1].
In vivo, licarbazepine is used as an anticonvulsant to treat epilepsy. It has mood-stabilizing effects. It is the active metabolite of oxcarbazepine and is responsible for the therapeutic effects of the parent drug. It has been approved for use in Europe since 2009. |
| Enzyme Assay |
Cell-free assays for licarbazepine are not standard because it targets ion channels. Its ability to block sodium channels can be assessed using electrophysiological techniques on isolated membranes or cells expressing sodium channels. Its binding to sodium channels can be studied using radioligand binding assays. Its purity is confirmed by HPLC.
|
| Cell Assay |
Cellular assays for licarbazepine are performed using neuronal cell lines or primary neurons. Cells are treated with varying concentrations of licarbazepine, and sodium currents are measured using patch-clamp electrophysiology. Its ability to inhibit action potential firing is assessed. Cell viability is evaluated using MTT assays.
|
| Animal Protocol |
In vivo animal experiments for licarbazepine are conducted in animal models of epilepsy, such as the maximal electroshock (MES) test or pentylenetetrazole-induced seizure models. Animals are administered licarbazepine orally or intraperitoneally, and seizure threshold, duration, and severity are assessed. Its anticonvulsant efficacy is confirmed.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Known metabolites of 10-hydroxycarbazine include (2S,3S,4S,5R)-6-[(11-carbamoyl-5,6-dihydrobenzo[b][1]benzozazepine-5-yl)oxy]-3,4,5-trihydroxyoxacyclohexane-2-carboxylic acid. Licarbazepine has a molecular weight of 254.28 g/mol and a molecular formula of C15H14N2O2. It is a carboxamide compound. It is soluble in DMSO and should be stored under recommended conditions. Its pharmacokinetic properties include good oral bioavailability and brain penetration. |
| Toxicity/Toxicokinetics |
The toxicological profile of licarbazepine is consistent with sodium channel blockers. Common side effects include dizziness, drowsiness, and ataxia. Serious adverse effects are rare but may include hyponatremia and skin reactions. It is contraindicated in patients with known hypersensitivity. Its safety profile is well established.
|
| References | |
| Additional Infomation |
Licarbazepine is a dibenzo[b,f]azapine, a dibenzo[b,f]azapine compound. It is reduced at C-10 and C-11, with a carbamoyl substituent on the nitrogen atom and a hydroxyl group at C-10. It is a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects. It is structurally related to oxcarbazepine and is its active metabolite. Licarbazepine acts as a sodium channel blocker, anticonvulsant, and drug allergen. It is a carboxamide compound, belonging to the dibenzo[b,f]azapine class, and is also a urea compound. Its function is similar to carbamazepine.
Licarbazepine is an anticonvulsant drug used to treat epilepsy. It is the active metabolite of oxcarbazepine and is structurally related to carbamazepine. It acts as a voltage-gated sodium channel blocker with anticonvulsant and mood-stabilizing effects. It was approved for use in Europe in 2009. It is also known as BIA 2-005 and GP 47779. |
| Molecular Formula |
C15H14N2O2
|
|---|---|
| Molecular Weight |
254.289
|
| Exact Mass |
254.106
|
| CAS # |
29331-92-8
|
| Related CAS # |
Licarbazepine-d3;1189917-36-9;Licarbazepine-d4;1020719-39-4;Licarbazepine-d4-1;1188265-49-7
|
| PubChem CID |
114709
|
| Appearance |
White to off-white solid powder
|
| Density |
1.336g/cm3
|
| Boiling Point |
431.3ºC at 760mmHg
|
| Melting Point |
186-189ºC
|
| Flash Point |
214.6ºC
|
| Vapour Pressure |
3.33E-08mmHg at 25°C
|
| Index of Refraction |
1.677
|
| LogP |
3.258
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
19
|
| Complexity |
347
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BMPDWHIDQYTSHX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)
|
| Chemical Name |
5-hydroxy-5,6-dihydrobenzo[b][1]benzazepine-11-carboxamide
|
| Synonyms |
TRI-477 BIA2-005BIA-2-005 GP47779 LIC477GP-47779 LIC-477 LIC-477D LIC477D TRI477GP-47779 BIA-2-005 Licarbazepine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~393.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.83 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (9.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.9325 mL | 19.6626 mL | 39.3252 mL | |
| 5 mM | 0.7865 mL | 3.9325 mL | 7.8650 mL | |
| 10 mM | 0.3933 mL | 1.9663 mL | 3.9325 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
